{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T04:04:56Z","timestamp":1788408296422,"version":"build-2803163510"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2005,8,9]],"date-time":"2005-08-09T00:00:00Z","timestamp":1123545600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1007\/s00432-005-0023-2","type":"journal-article","created":{"date-parts":[[2005,8,8]],"date-time":"2005-08-08T10:59:32Z","timestamp":1123498772000},"page":"105-112","source":"Crossref","is-referenced-by-count":89,"title":["Bendamustine, vincristine and prednisone (BOP) versus cyclophosphamide, vincristine and prednisone (COP) in advanced indolent non-Hodgkin\u2019s lymphoma and mantle cell lymphoma: results of a randomised phase III trial (OSHO# 19)"],"prefix":"10.1007","volume":"132","author":[{"given":"M.","family":"Herold","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Niederwieser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Franke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. J.","family":"Fricke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P.","family":"Richter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Freund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Ismer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Dachselt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Boewer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Schirmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Weniger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Pasold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Winkelmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Klinkenstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Arzberger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Bremer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Hahnfeld","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Schwarzer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chr.","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the East German Study Group Hematology and Oncology (OSHO)","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,8,9]]},"reference":[{"issue":"2","key":"23_CR1","doi-asserted-by":"crossref","first-page":"227","DOI":"10.7326\/0003-4819-76-2-227","volume":"76","author":"CM Bagley","year":"1972","unstructured":"Bagley CM, Devita VT, Berard CW, Canellos GP (1972) Advanced lymphosarcoma: intensive cyclical combination chemotherapy with cyclophosphamide, vincristine, and prednisone. Ann Intern Med 76(2):227\u2013234","journal-title":"Ann Intern Med"},{"issue":"Suppl 2","key":"23_CR2","first-page":"149","volume":"77","author":"K Blumenstengel","year":"1999","unstructured":"Blumenstengel K, Fricke H-J, Kath R, H\u00f6ffken K (1999) Bendamustine(B), vincristine(O), prednisolone(P) in relapsed and refractory low-grade non-Hodgkin\u2019s lymphomas (NHL). Ann Hematol 77(Suppl 2):149 (Abstr 591)","journal-title":"Ann Hematol"},{"issue":"11","key":"23_CR3","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1007\/s00432-002-0378-6","volume":"128","author":"K Bremer","year":"2002","unstructured":"Bremer K (2002) High rates of long-lasting remissions after 5-day bendamustine chemotherapy cycles in pre-treated low-grade non-Hodgkin\u2019s lymphomas. J Cancer Res Clin Oncol 128(11):603\u2013609","journal-title":"J Cancer Res Clin Oncol"},{"key":"23_CR4","first-page":"1","volume":"17","author":"K Bremer","year":"1996","unstructured":"Bremer K, Roth W (1996) Bendamustine, a low toxic nitrogen-mustard derivative with high efficacy in malignant lymphomas. Tumordiagn u Ther 17:1\u20136","journal-title":"Tumordiagn u Ther"},{"issue":"5","key":"23_CR5","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1016\/S0006-2952(03)00410-6","volume":"66","author":"KU Chow","year":"2003","unstructured":"Chow KU, Nowak D, Boehrer S, Ruthardt M, Knau A, Hoelzer D, Mitrou PS, Weidmann E (2003) Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol 66(5):711\u2013724","journal-title":"Biochem Pharmacol"},{"issue":"10","key":"23_CR6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.1987.5.10.1670","volume":"5","author":"DO Dixon","year":"1987","unstructured":"Dixon DO, McLaughlin P, Hagemeister FB, Freireich EJ, Fuller LM, Cabanillas FF, Gehan EA (1987) Reporting outcomes in Hodgkin\u2019s disease and lymphoma. J Clin Oncol 5(10):1670\u20131672","journal-title":"J Clin Oncol"},{"issue":"5","key":"23_CR7","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1182\/blood.V84.5.1361.1361","volume":"84","author":"NL Harris","year":"1994","unstructured":"Harris NL, Jaffe ES, Stein H (1994) A revised European-American classification of lymphoid neoplasm: a proposal from the International Lymphoma Study Group. Blood 84(5):1361\u20131392","journal-title":"Blood"},{"issue":"9","key":"23_CR8","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1097\/00001813-200110000-00003","volume":"12","author":"A Heider","year":"2001","unstructured":"Heider A, Niederle N (2001) Efficacy and toxicity of bendamustine in patients with relapsed low-grade non-Hodgkin\u2019s lymphomas. Anticancer Drugs 12(9):725\u2013729","journal-title":"Anticancer Drugs"},{"issue":"11","key":"23_CR9","doi-asserted-by":"crossref","first-page":"169a","DOI":"10.1182\/blood.V104.11.584.584","volume":"104","author":"M Herold","year":"2004","unstructured":"Herold M, Pasold R, Srock S, Neser S, Niederwieser D, Neubauer A, D\u00f6lken G, Naumann R, Fietz T, Freund M, Rohrberg R, Hoeffken K, Franke A, Ittel TH, Kettner E, Haak U, Mey U, Klinkenstein U, Assmann M, von Gruenhagen U, Dachselt K, Schwenke H, Bleyl D, Wolf H, Hahnfeld S, Hoffmann F-A, Lakner V, Richter P, H\u00e4hling D, Wolf HH, Eschenburg H, Clemens M-R, Grobe N (2004) Results of a prospective randomised open label phase iii study comparing rituximab plus mitoxantrone, chlorambucile, prednisolone chemotherapy (R-MCP) versus MCP alone in untreated advanced indolent non-hodgkin\u2019s lymphoma (NHL) and mantle-cell-lymphoma (MCL). Blood 104(11):169a (Abstr 584)","journal-title":"Blood"},{"key":"23_CR10","first-page":"279","volume-title":"Kompendium Internistische Onkologie","author":"W Hiddemann","year":"1999","unstructured":"Hiddemann W, Schmoll H-J, Theml H, Hoffmann W (1999) Follikul\u00e4res Keimzentrumslymphom (zentroblastisch-zentrozystisches Lymphom). In: Schmoll, H\u00f6ffken, Possinger (eds) Kompendium Internistische Onkologie, 3rd edn. Springer, Berlin, Heidelberg, New York, pp 279\u2013296","edition":"3rd edn"},{"key":"23_CR11","doi-asserted-by":"crossref","unstructured":"Hiddemann W, Forstpointner R, Kneba M, Schmitz N, Schmits R, Metzner B, Reiser M, Lengfelder E, Woermann B, Harder H, Hegewisch-Becker S, Bredel W, Hess G, Eimermacher H, Aldaoud A, Planker M, Rarwaresch R, Dreyling M, Unterhalt M (2004) The addition of rituximab to combination chemotherapy with CHOP has a long lasting impact on subsequent treatment in remission in follicular lymphoma but not in mantle cell lymphoma: results of two prospective randomized studies of the German Low Grade Lymphoma Study Group (GLSG) 104(11):50a (Abstr 161)","DOI":"10.1182\/blood.V104.11.161.161"},{"key":"23_CR12","unstructured":"Karnekal S, Crain B, Elliott G, Singh S (2004) SDX-105 (Bendamustine) Inhibits Growth of SU-DHL-1 and Daudi lymphoma xenografts in SCID Mice. PROC AACR 45 (Abstr 4575)"},{"key":"23_CR13","unstructured":"Lennert K, Feller AC (1990) In: Histopathologie der non-Hodgkin-lymphome (nach der aktualisierten Kiel-Klassifikation), 2nd edn. Springer, Berlin, Heidelberg, New York, p 15"},{"issue":"11","key":"23_CR14","first-page":"640a","volume":"102","author":"LM Leoni","year":"2003","unstructured":"Leoni LM, Bailey B, Reifert J (2003) SDX-105 (Bendamustine), a clinically active antineoplastic agent possesses a unique mechanism of action. Blood 102(11):640a (Abstr 2363)","journal-title":"Blood"},{"key":"23_CR15","unstructured":"Leoni LM, Bailey B, Reifert J, Niemeyer C, Bendall H, Dauffenbach L, Kerfoot C (2004) In\u00a0vitro and ex\u00a0vivo activity of SDX-105 (Bendamustine) in drug-resistant lymphoma cells. PROC AACR 45 (Abstr 1215)"},{"key":"23_CR16","unstructured":"Niemeyer C, Bailey B, Reifert J, Bendall H, Corbeil J, Leoni LM (2004) SDX-105 (Bendamustine) is a clinically active chemotherapeutic agent with a distinct mechanism of action. PROC AACR 45 (Abstr 1129)"},{"key":"23_CR17","first-page":"3","volume":"109","author":"C P\u00f6tscher","year":"2000","unstructured":"P\u00f6tscher C, Hiller E, Busch M, Unterhalt M, Hiddemann W (2000) Aktuelle Therapiekonzepte follikul\u00e4rer Lymphome (zentroblastisch-zentrozytisch). Akt Onkol 109:3\u201320","journal-title":"Akt Onkol"},{"issue":"Suppl 3","key":"23_CR18","first-page":"125","volume":"10","author":"K Ruffert","year":"1999","unstructured":"Ruffert K (1999) Therapy of low grade non-Hodgkin\u2019s-lymphoma (NHL) with bendamustine and oral etoposide. Ann Oncol 10(Suppl 3):125 (Abstr 452)","journal-title":"Ann Oncol"},{"issue":"8","key":"23_CR19","first-page":"671","volume":"44","author":"K Ruffert","year":"1989","unstructured":"Ruffert K, Jahn H, Syrbe G, Stauch M, Jorke D, K\u00fchn R (1989) Cytostasan (Bendamustin) in der Alternativtherapie maligner Non-Hodgkin-Lymphome. Z Klin Med 44(8):671\u2013674","journal-title":"Z Klin Med"},{"issue":"16S","key":"23_CR20","first-page":"576s","volume":"23","author":"M-J Rummel","year":"2005","unstructured":"Rummel M-J, Al-Bartran S, Welslau M, Kofahl-Krause D, Duerk H, Hoelzer D, Mitrou PS (2005) Bendamustine and rituximab act synergistically in\u00a0vitro and are effective in the treatment of relapsed or refractory indolent and mantle cell lymphomas. J Clin Oncol 23(16S):576s (Abstr 6565)","journal-title":"J Clin Oncol"},{"issue":"4","key":"23_CR21","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00001813-199606000-00007","volume":"7","author":"D Strumberg","year":"1996","unstructured":"Strumberg D, Harstrick A, Doll K, Hoffmann B, Seeber S (1996) Bendamustine hydrochloride activity against doxorubicin-resistant human breast carcinoma cell lines. Anticancer Drugs 7(4):415\u2013421","journal-title":"Anticancer Drugs"},{"issue":"Suppl 1","key":"23_CR22","first-page":"453a","volume":"88","author":"M Unterhalt","year":"1996","unstructured":"Unterhalt M, Hermann R, Koch P, Tr\u00fcmper L, Bodenstein H, Dietzfelbinger H, Landys K, Reu\u00df M, Vetter H, Maschmeyer G, Freund M, Neubauer A, Engert A, Stauder R, Herold M, Tiemann M, Parwaresch R, Stein H, Hiddemann W (1996) Long term interferon alpha maintenance prolongs remission duration in advanced low grade lymphomas and is related to the efficacy of initial cytoreductive chemotherapy. Blood 88(Suppl 1):453a (Abstr 1801)","journal-title":"Blood"},{"issue":"4","key":"23_CR23","first-page":"483","volume":"25","author":"JM Vose","year":"1998","unstructured":"Vose JM (1998) Current approaches to the management of non Hodgkin\u2019s lymphoma. Semin Oncol 25(4):483\u2013491","journal-title":"Semin Oncol"},{"key":"23_CR24","unstructured":"Vose, JM (1999) Mantle cell lymphoma. In: Non-Hodgkin\u2019s lymphoma: treatment for the millenium. Proceedings of a symposium at the 41st annual meeting of the American Society of Hematology, New Orleans"},{"issue":"12","key":"23_CR25","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1080\/10428190400004521","volume":"45","author":"R Weide","year":"2004","unstructured":"Weide R, Pandorf A, Heymanns J, K\u00f6ppler H (2004) Bendamustine\/Mitoxantrone\/Rituximab (BMR): a very effective, well tolerated outpatient chemoimmunotherapy for relapsed and refractory CD20-positive indolent malignancies. Final results of a pilot study. Leuk Lymphoma 45(12):2445\u20132449","journal-title":"Leuk Lymphoma"},{"key":"23_CR26","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1007\/s001080050125","volume":"38","author":"F Weissinger","year":"1997","unstructured":"Weissinger F, Kreipe HH, Wilhelm M (1997) Non hodgkin lymphome. Internist 38:1131\u20131142","journal-title":"Internist"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-005-0023-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00432-005-0023-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-005-0023-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,4,8]],"date-time":"2020-04-08T19:04:28Z","timestamp":1586372668000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00432-005-0023-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,8,9]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["23"],"URL":"https:\/\/doi.org\/10.1007\/s00432-005-0023-2","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"value":"0171-5216","type":"print"},{"value":"1432-1335","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,8,9]]}}}